Chemotherapy protocols and incidence of oral mucositis. An integrative review (original) (raw)
Related papers
Investigation of Oral Mucositis Incidence and Risk Factors in Patients Receiving Chemotherapy
Journal of basic and clinical health sciences, 2023
Oral mucositis is a common complication of cancer treatment that may negatively impact the patient's cancer treatment outcome. This study was done to determine the incidence of oral mucositis development and risk factors in patients receiving chemotherapy. Material and Methods: This cross-sectional study included 150 participants undergoing outpatient cancer chemotherapy. To determine the development of oral mucositis, the participants were evaluated for the first course of chemotherapy (day 0) and the next course of chemotherapy treatment (day 14). 'Patient Information Form' and the World Health Organization' Mucositis Grading Scale' were used to collect data for the study. Descriptive statistics, and logistic regression were used to analyze the results. Results: According to oral mucosal assessment, incidence of oral mucositis was 27.3%. The mean onset and the mean recovery of oral mucositis were 4.16 ± 2.13 days and 8.72 ± 2.32 days. The most common oral problems were mouth dryness (53.3%), dental caries (44%), and decreased sense of taste (32%). In the oral mucosal assessment performed on the 14th day, 9 patients were found to be grade 1. Patients with a history of mucositis (OR = 5.76, Cl = 2.33-14.24, p = 0.00) showed a significantly higher incidence of oral mucositis. Conclusion: In this study, the incidence of oral mucositis and risk factors that may affect the development of oral mucositis in patients receiving chemotherapy were investigated. Mucositis history was found as a risk factor in oral mucositis development. Early recovery of oral mucositis after chemotherapy was observed. Therefore, patients should be followed up in the early period after chemotherapy.
Oral mucositis: the hidden side of cancer therapy
Journal of Experimental & Clinical Cancer Research
Inflammation response of epithelial mucosa to chemo- radiotherapy cytotoxic effects leads to mucositis, a painful side effect of antineoplastic treatments. About 40% of the patients treated with chemotherapy develop mucositis; this percentage rises to about 90% for head and neck cancer patients (HNC) treated with both chemo- and radiotherapy. 19% of the latter will be hospitalized and will experience a delay in antineoplastic treatment for high-grade mucositis management, resulting in a reduction of the quality of life, a worse prognosis and an increase in patient management costs. Currently, several interventions and prevention guidelines are available, but their effectiveness is uncertain. This review comprehensively describes mucositis, debating the impact of standard chemo-radiotherapy and targeted therapy on mucositis development and pointing out the limits and the benefits of current mucositis treatment strategies and assessment guidelines. Moreover, the review critically exam...
Oral mucositis in cancer treatment: Natural history, prevention and treatment
Molecular and clinical oncology, 2014
Oral mucositis is a condition that is characterized by ulcerative lesions in the mucosa of patients undergoing radiotherapy or chemotherapy. Oral mucositis is currently considered to be the most severe complication of anticancer therapy, affecting 40-80% of patients undergoing chemotherapy and almost all those undergoing radiotherapy of the head and neck. Although they do not prevent lesions from appearing, drugs for the treatment of oral mucositis are required to minimize its clinical aggressiveness and improve the nutritional status, hydration and quality of life of the affected patients. Furthermore, the prevention and control of oral ulcers is crucial for cancer prognosis, since the establishment of severe lesions may lead to temporary or permanent treatment discontinuation and compromise cancer control. The objective of this study was to present a review on this condition, its causes and its treatment to professional clinical dentists, in order to help minimize patient sufferin...
International Journal of Nursing Practice
Aim: The aims of the study are to determine the incidence of oral mucositis, the stage of the condition, risk factors, and other oral complications in patients receiving outpatient chemotherapy and to evaluate the factors that have an impact on these. Methods: The study included 147 patients undergoing outpatient cancer chemotherapy at the Chemotherapy Unit of a University Hospital between February and April 2015. We used a questionnaire and the World Health Organization "Mucositis Grading Scale". Chi-squared tests were used to determine the relationships between factors, and multiple logistic regression analysis was employed to explore predictive factors. Results: The frequency of oral mucositis was 51.7%. The most common oral problems were mouth dryness (55.1%), a reduced/changed sense of taste (52.4%), and a lack of appetite (47.6%). Logistic regression analysis showed that the risk factors for oral mucositis were advanced age, a lack of appetite, and the duration of chemotherapy. Conclusions: As a result, half of all patients undergoing outpatient cancer chemotherapy developed oral mucositis. Patients are unable to adequately prevent oral mucositis and carry out oral care. It is recommended that more studies be conducted in outpatient units to evaluate predictive factors for oral mucositis.
Current Trends in Management of Oral Mucositis in Cancer Treatment
Asian Pacific journal of cancer prevention : APJCP, 2017
Oral Mucositis (OM) is among the most common and dreaded toxicities of cancer therapy. It occurs in almost all patients who receive radiation therapy in which areas of oral and oropharyngeal mucosa are included in the treatment field. With the advent of chemotherapy in 1940 and its extended clinical legacy, it is only within the past two decade or so that mucositis’ complex pathobiology has become fully appreciated. There are still many unanswered questions about the risk factors for developing OM, but historically, risk factors have been attributed to both therapy and patient m characteristics. One thing that has been consistent from the initial descriptions of its clinical manifestations has been the frustration on the part of clinicians and patients with the scarcity of therapeutic options to prevent or treat the condition, or effectively ameliorate the symptoms. Clinicians, researchers and those involved in oral and periodontal medicine should join hand in hand in persuit of und...
Current trends in the management of oral mucositis related to cancer treatment
The Malaysian journal of medical sciences : MJMS, 2008
Oral mucositis is one of the most common toxicities observed during radiotherapy and chemotherapy treatment for cancers. Mucositis results in sore mouth, altered taste sensation, pain and dysphagia leading to malnutrition. Left untreated, oral mucositis leads to ulceration, orodental infection, bleeding and discontinuation of effective radiotherapy or chemotherapy. Frequent hospitalization, enteral or parenteral nutrition, increased demand for analgesics ultimately account for increased cost of healthcare. Quantification of oral mucositis using standardized grading system is important for appropriate evaluation, reporting and management. In the recent past there is a paradigm shift in the pathobiology of cancer therapy related mucositis. Clear understanding of its pathogenesis is essential for the formulation of effective mucositis care. Numerous drug therapies, radiation techniques and oral care protocols have been tried in the past to reduce oral mucositis, None have proven to be ...
International journal of environmental research and public health, 2018
This study analyzes the factors contributing to the duration of severe oral mucositis in oncopediatric patients. A longitudinal study was conducted in the pediatric department of a cancer referral hospital between 2013 and 2017. Seventy-three patients diagnosed with cancer undergoing chemotherapy protocols were analyzed. Oral evaluations were performed using the criteria, and the data were collected from the patients' records. The Kaplan-Meier method was used to estimate survival curves. Most patients were males (52.1%), of mixed race ("pardo") (49.3%), with a mean age of 7.56 years (±5.34). There was a predominance of patients diagnosed with solid tumors (52.1%), with no metastasis (86.3%), using natural product chemotherapeutics (56.2%), who had not undergone a bone marrow transplant (97.3%); amputation was observed in 35.6% of patients, while death rates were as high as 8.2%. The survival analysis estimated a mean time of 30.6 days until complete remission of severe...
Oral mucositis in cancer treatment: Natural history, prevention and treatment (Review)
Molecular and Clinical Oncology, 2014
Oral mucositis is a condition that is characterized by ulcerative lesions in the mucosa of patients undergoing radiotherapy or chemotherapy. Oral mucositis is currently considered to be the most severe complication of anticancer therapy, affecting 40-80% of patients undergoing chemotherapy and almost all those undergoing radiotherapy of the head and neck. Although they do not prevent lesions from appearing, drugs for the treatment of oral mucositis are required to minimize its clinical aggressiveness and improve the nutritional status, hydration and quality of life of the affected patients. Furthermore, the prevention and control of oral ulcers is crucial for cancer prognosis, since the establishment of severe lesions may lead to temporary or permanent treatment discontinuation and compromise cancer control.
Oral Mucositis Induced By Anticancer Therapies
Current Oral Health Reports, 2015
Oral mucositis induced by conventional cytotoxic cancer therapies is a common and significant clinical problem in oncology. Mucositis symptoms, which include severe pain, may lead to dose reductions and unplanned interruptions of chemotherapy and/or radiotherapy, and often affect patients' quality of life. In addition, ulcerative mucositis represents a risk factor for local or systemic infectious complications that may be life-threatening in immunosuppressed patients. The development of biologically based targeted cancer therapies, which aim to block the growth, spread, and survival of tumors by interfering with specific molecular targets, may have reduced mucosal injury, but did not eliminate it. This article will review the epidemiology, pathobiology, and management of oral mucositis associated with conventional cytotoxic therapies for malignant diseases and will briefly summarize emerging information on oral mucosal injury associated with targeted therapies. Considerations for future research aimed at the development of more efficient and effective supportive care approaches will be presented, with emphasis on the contribution of dental researchers and clinicians in these efforts.